How (not) to mobilize health workers in the fight against vaccine hesitancy: Experimental evidence from Germany’s AstraZeneca controversy

Table 10 Adjusted p-values for multiple hypothesis testing

Parameter	AZ	J & J	Moderna	Pfizer	Sinopharm	Sputnik-V
	(1)	(2)	(3)	(4)	(5)	(6)
Full Sample
T1	0.000	0.045	0.392	0.392	0.005	0.054
T2	0.901	0.519	0.835	0.901	0.023	0.231
T3	0.890	0.810	0.966	0.890	0.810	0.685
T4	0.977	0.929	0.992	0.992	0.806	0.268
Women Sample
T1	0.000	0.108	0.228	0.165	0.020	0.139
T2	0.937	0.663	0.937	0.896	0.121	0.491
T3	0.947	0.895	0.947	0.947	0.947	0.728
T4	0.981	0.981	0.942	0.977	0.976	0.890
Men Sample
T1	0.210	0.552	0.889	0.768	0.352	0.464
T2	0.946	0.868	0.790	0.946	0.357	0.614
T3	0.987	0.987	0.679	0.854	0.854	0.987
T4	0.865	0.407	0.516	0.865	0.516	0.139
State FE	Yes	Yes	Yes	Yes	Yes	Yes
Basic Controls	Yes	Yes	Yes	Yes	Yes	Yes

Notes: ‘AZ’ refers to AstraZeneca, ‘J & J’ refers to Johnson & Johnson, and ‘Pfizer’ refers to Pfizer/BioNTech. State FE include controls for respondents place of residence (state). Basic controls include respondent’s age, gender, education, and survey specifics (order of vaccine-related questions, platform, device). P-value adjustments were calculated based on 2,000 replications using the RWOLF package in STATA

ISSN: 1471-2458